Shanghai Hile Bio-tech (603718) — Working Capital to Net Assets Ratio
Shanghai Hile Bio-tech (603718) has a Working Capital to Net Assets ratio of 48.3% as of March 2026. Working capital of CN¥452.12 Million (current assets of CN¥590.55 Million minus current liabilities of CN¥138.43 Million) is measured against net assets of CN¥936.02 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See 603718 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shanghai Hile Bio-tech Working Capital to Net Assets (2011–2025)
This chart shows how Shanghai Hile Bio-tech's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 48.3%, reflecting working capital of CN¥452.12 Million against net assets of CN¥936.02 Million CNY. See Shanghai Hile Bio-tech (603718) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Shanghai Hile Bio-tech (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shanghai Hile Bio-tech from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Shanghai Hile Bio-tech (603718) total market value.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 54.1% | CN¥484.30 Million | CN¥895.97 Million | CN¥595.84 Million | CN¥111.54 Million | ▲ +19.3 pp |
| 2024 | 34.7% | CN¥591.53 Million | CN¥1.70 Billion | CN¥691.77 Million | CN¥100.25 Million | ▲ +22.3 pp |
| 2023 | 12.4% | CN¥145.51 Million | CN¥1.17 Billion | CN¥562.55 Million | CN¥417.04 Million | ▼ -18.6 pp |
| 2022 | 31.0% | CN¥344.28 Million | CN¥1.11 Billion | CN¥665.03 Million | CN¥320.75 Million | ▲ +0.0 pp |
| 2021 | 30.9% | CN¥305.48 Million | CN¥987.19 Million | CN¥975.44 Million | CN¥669.96 Million | ▲ +20.3 pp |
| 2020 | 10.7% | CN¥102.48 Million | CN¥962.20 Million | CN¥742.49 Million | CN¥640.01 Million | ▼ -6.0 pp |
| 2019 | 16.7% | CN¥165.50 Million | CN¥992.57 Million | CN¥805.84 Million | CN¥640.34 Million | ▲ +4.0 pp |
| 2018 | 12.7% | CN¥130.15 Million | CN¥1.03 Billion | CN¥787.47 Million | CN¥657.31 Million | ▼ -20.9 pp |
| 2017 | 33.6% | CN¥361.21 Million | CN¥1.07 Billion | CN¥818.47 Million | CN¥457.27 Million | ▼ -23.0 pp |
| 2016 | 56.6% | CN¥569.15 Million | CN¥1.01 Billion | CN¥828.52 Million | CN¥259.38 Million | ▼ -14.2 pp |
| 2015 | 70.8% | CN¥682.02 Million | CN¥963.31 Million | CN¥787.99 Million | CN¥105.97 Million | ▲ +16.1 pp |
| 2014 | 54.7% | CN¥305.41 Million | CN¥558.50 Million | CN¥352.53 Million | CN¥47.12 Million | ▼ -3.5 pp |
| 2013 | 58.2% | CN¥291.26 Million | CN¥500.66 Million | CN¥354.41 Million | CN¥63.15 Million | ▲ +5.6 pp |
| 2012 | 52.6% | CN¥246.08 Million | CN¥467.89 Million | CN¥309.88 Million | CN¥63.80 Million | ▲ +11.2 pp |
| 2011 | 41.4% | CN¥167.81 Million | CN¥405.74 Million | CN¥244.96 Million | CN¥77.15 Million | — |